Artemis Medicare Services Ltd (ARTEMISMED) Q2FY27 Concall Summary - Sep-2026 Qtr
Key Takeaways
- Management plans a fund-raise by January-February 2027 to acquire large, EBITDA-positive hospitals, with targets in Delhi NCR and Eastern/Central India nearing finalization.
- The new Raipur hospital's ARPOB of INR 30-32k has significantly exceeded initial estimates, signaling strong potential for profitability, with breakeven targeted within 12-15 months.
- Potential regulatory price caps on oncology drugs are estimated to have a minimal EBITDA impact of 0.5-0.8%, according to management's worst-case analysis.
Performance Overview
- Artemis Medicare reported its highest-ever EBITDA of 23.8% for its Gurgaon hospital in Q2 FY27.
- Consolidated revenue grew 13.2% year-on-year, driven by strong demand in key specialties like cardiac sciences, oncology, and transplants.
- The new 300-bed Artemis Shanti Hospital in Raipur commenced operations in July 2026, marking the company's expansion into Central India.
- International patients contributed approximately 30% of revenue during the quarter, with a diversified base from over 150 countries.
- The company is progressing with expansion plans, including adding 250 beds at the Gurugram campus and developing a 650+ bed hospital in South Delhi.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.
Tone & Disclosure
Log in to Stocksigma to read the Tone & Disclosure section of this summary.